MRK

Monthly 47-11-1 bull market is intact, grade C

I count forty seven winners, eleven losers, one break even trade for the June option cycle. While I made money, I had my first whopper loss for 2015 plus a stupid trade so grade is a C. Both the big loser and whopper loss were in AMBA. I also got whipsawed in JBLU and MRK. I made money in SKX, […]

Biotech Stock News (RXII)(REGN)(SNY)(ESPR)(ISIS)(BIIB) | CNA …

Rxi Pharmaceuticals (NASDAQ:RXII)On June 9, 2015 shares of Rxi Pharmaceuticals went up 6% after the company reported that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. The new patents establish a few new details that enhance upon the company’s prospects:First the new patent is for a chemical modification that allows for […]

Warning: Top Healthcare Performers Now Overvalued

ShareOver the past five years, one sector has outperformed all others in the S&P 500: healthcare.Biotech stocks have led the way, with the Nasdaq Biotechnology Index climbing a whopping 520% since early 2009.The sector’s incredible run hasn’t dampened enthusiasm for the future, either. Healthcare stocks continue to receive bullish outlooks, and some are even taking on an air of invincibility.In […]

Why Pfizer Will Trade At $40 On Improved Drug Pipeline – Pfizer Inc …

SummaryWith the stock trading at a P/E of 9, these shares are still cheap.
Pfizer is trading at a P/E that is almost 30 points below Merck (MRK), 13 points below Novartis (NVS) and 15 point below Sanofi (SNY).
At around $30 per share, investors that are looking for exposure in the health care industry and values 3.5% dividend yield should not […]

Alnylam names new program ALN-HBV to its pipeline

moreView todays social media effects on MRKView the latest stocks trending across Twitter. Click to view dashboardSee who Merck is hiring next, click here to view […]

7:31 am Merck: FDA approves ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or with peripheral arterial disease

moreView todays social media effects on MRKView the latest stocks trending across Twitter. Click to view dashboardSee who Merck is hiring next, click here to view […]

FDA Approves ZONTIVITYâ„¢ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved ZONTIVITYâ„¢ for the reduction of thrombotic cardiovascular events in patients with a history of heart at moreView todays social media effects on MRKView the latest stocks trending across Twitter. Click to view dashboardSee who Merck […]